GERM

ETFMG Treatments, Testing and Advancements ETF

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-515.2K ExitQ3 2024 $515k -- --

Trade GERM

About ETFMG Treatments, Testing and Advancements ETF

This fund aims to replicate the investment performance of U.S.-listed companies, including equity shares and depositary receipts, that are primarily engaged in two sectors: either researching, developing, and bringing to market treatments or vaccines for infectious diseases, or producing, researching, and supplying biological diagnostic tests for patients. At least 80% of the fund's total assets will be invested in the specific securities that constitute its underlying index. It is important to note that this fund is structured as non-diversified.

IPO Date: Jun 18, 2020

Market Data

Open: $19.28
High: $19.28
Low: $19.16
Volume: 4.8K
Avg Volume: 1.2K
52W High: $20.20
52W Low: $16.32

Valuation

Market Cap: $9.6M
Dividend Yield: 8.80%

Financials

Financial statement snapshot is not available yet.

Events

DividendJun 27

$0.087987